Amarantus Restart Makes Another Run at MANF Protein
By Catherine Shaffer
Friday, June 15, 2012
Amarantus Biosciences Inc. is an early stage biotech devoted to controlling diseases related to programmed cell death. Its lead program focuses on mesencephalic astrocyte-derived neurotrophic factor (MANF) as a therapeutic protein for conditions such as Parkinson's disease and traumatic brain injury.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.